9th Annual Biomarkers Congress

View Profile


Speaking/Presenting-Abstract/Poster at Mtg

Topic Authors / presenters Event name Event date
1. T-cell Epitope Vaccine Provides Complete Protection Against Lethal Vaccinia Infection In HLA Transgenic Mouse Model , abstract, Vaccine Technology III, Nuevo Vallarta June, 2010
2. Personalizing Immune Responses to Vaccines, Autoantigens, and Protein Therapeutics: The iTEM (individualized T Cell Epitope Measure) Tool Vaccine Technology III, Nuevo Vallarta June, 2010
3. De-Tolerization of Anti-DEC205 for HIV Subunit Vaccine Delivery Vaccine Technology III, Nuevo Vallarta June, 2010
4. Universal Flu Vaccines: Now more than Ever abstract, Vaccine Technology III, Nuevo Vallarta June, 2010
5. Suppression of CTL Responses against AAV-Capsid Epitopes by Peptide-Induced Regulatory T Cells American Society for Hematology, Oral Session: Gene Therapy and Transfer. December, 2009
6. De-tolerization of anti-dec-205 for HIV subunit vaccine delivery. Poster # 131453, Cold Spring Harbor Laboratory. Meeting, “Harnessing immunity to prevent and treat disease October, 2009
7. Effective design of T-cell driven vaccines applied to the GAIA HIV vaccine: advances in vaccine design based on current preclinical success. AIDS Vaccine 2009. October, 2009
8. Regulatory T cell epitopes in a dendritic cell-targeted HIV vaccine delivery platform. P19-43. AIDS Vaccine 2009. Paris, France. 19 to 22 October 2009. Retrovirology, Volume 6 Suppl 3. October, 2009
9. VennVax: T cell mediated protection against aerosol challenge; Epitope Driven Vaccines 3rd Vaccine Congress, Singapore October, 2009
10. Effect of Tregitopes on T1D immune response in vitro and diabetes in NOD mice 1st International Conference on Immune Tolerance October, 2009
11. De-tolerization of anti-DEC-205 for HIV subunit vaccine delivery 1st International Conference on Immune Tolerance October, 2009
12. Regulatory T cell epitope IgG Fc derived peptide (Tregitope) modulates tolerance/immunogenicity balance in murine and human allo-antigen stimulation models. 1st International Conference on Immune Tolerance, Boston MA 25 - 27th October 2009. October, 2009
13. T-cell Epitope Vaccine Protects HLA Transgenic Mice Against Lethal Vaccinia Challenge Without B Cell Priming Poster # 131452, Cold Spring Harbor Laboratory. Meeting October, 2009
14. Immunoinformatic-discovered mycobacterium tuberculosis T-cell epitopes are immunogenic in HLA transgenic mice. Poster # 131449, Cold Spring Harbor Laboratory. Meeting October, 2009
15. A new tool for vaccine design and personal therapeutics. Poster # 131448, Cold Spring Harbor Laboratory. Meeting October, 2009
16. New Vaccines for Old Diseases CMB Seminar, University of Rhode Island September, 2009
17. T cell epitopes (Tregitopes) contained in IgG Constant Domains activate natural Tregs: Relevance for autoimmune disease, gene therapy, and less immunogenic biologics. Oral Presentation, WSD18/. 2nd European Congress of Immunology September, 2009
18. De-immunization of Human Factor VIII: Identification of Epitopes in the C2 Domain. Oral presentation. WSD14/1. 2nd European Congress of Immunology September, 2009
19. Effect of Tregitopes on T1D Immune response in vitro and on diabetes in NOD mice. oral presentation. WSC11/3. 2nd European Congress of Immunology September, 2009
20. Effect of Tregitope on immune response to T1D antigens in vitro and on diabetes in NOD mice 2nd European Congress of Immunology September, 2009
21. De-immunization” of Human Factor VIII: Identification of Epitopes in the C2 Domain 2nd European Congress of Immunology September, 2009
22. T cell epitopes (Tregitopes) contained in IgG Constant Domains activate natural Tregs:Relevance for autoimmune disease, gene therapy, and less immunogenic biologics. Oral Presentation, WSD18/. 2nd European Congress of Immunology September, 2009
23. De tolerization of anti-DEC 205 for HIV subunit vaccine delivery. PD01/14. DEC205 ECI/Berlin September, 2009
24. T cell epitopes (Tregitopes) contained in IgG Constant Domains activate Natural Tregs 1st International Conference on Tolerance, Boston MA. Sept 2009. Elsevier. September, 2009
25. Immuno-modulatory functions of a novel IgG Fc-derived Peptides, Tregitopes, in alloimmunity Oral presentation. Young Investigator Award (DeAddio) American Transplant Conference June, 2009
26. Enhancing Safety for Protein Therapeutics by (1) Reducing Immunogenicity and (2) Tolerance Induction Seminar at the National Institute of Health Sciences, Japan June, 2009
27. Reducing protein immunogenicity by Design: Deimmunization and tolerance induction 21st ESACT Meeting June, 2009
28. Enhancing Safety by Reducing Immunogenicity through Tolerance Induction. FDA May, 2009
29. Immunome-derived, Epitope-driven vaccine design Laboratory of Parasitic Disease, NIH May, 2009
30. Patient adherence to HIV treatment and prevention in the Centre de Santé Communautaire de Sikoro, Bamako, Mali Poster and Abstract 0294. 4th International Conference on HIV Treatment Adherence April, 2009
31. De-tolerization of anti-DEC-205 for HIV subunit vaccine delivery. HIV Immunobiology: From Infection to Immune Control March, 2009
32. Weber Effective design of T-cell driven vaccines applied to the GAIA HIV vaccine Advances in vaccine design based on current preclinical success Prevention of HIV/AIDS March, 2009
33. Knowledge, Attitudes, Practices and Willingness to Participate in HIV Vaccine trials among urban residents of Bamako, Mali, in West Africa. Poster presentation. HIV Immunobiology: From Infection to Immune Control (X4) March 22 - March 27, 2009 Keystone Resort, Keystone, Colorado March, 2009
34. T-cell Epitope Vaccine Protects HLA Transgenic Mice Against Lethal Vaccinia Challenge. NFID, Baltimore March, 2009
35. Rapid development and validation of a T-cell epitope-based Tularemia vaccine for F. Tularensis Poster Presentation. NFID, Baltimore March, 2009
36. HelicoVax - a genome-derived vaccine candidate developed from T cell epitopes conserved between human and mouse-adapted strains of H. pylori. Oral Presentation. NFID, Baltimore March, 2009
37. Tuberculosis Knowledge, Attitudes and Practices in Sikoro, Mali. 14th Annual North American International Union Against Tuberculosis and Lung Disease (IUATLD NA) conference will be held in Orlando Florida March, 2009
38. Knowledge, Attitudes, Practices and Willingness to Participate in HIV Vaccine trials among urban residents of Bamako, Mali, in West Africa Prevention of HIV/AIDS (X3) Dates March, 2009
39. Reducing Protein Immunogenicity by Design: Deimmunization and Tolerance Induction Emerging, "Disruptive" Technologies: Disruptive Science and Technology Session, Accelerating Biopharmaceutical Development, San Diego March, 2009
40. Antigen-specific modulation of CTL responses triggered by AAV-capsid epitope presentation on transduced hepatocytes American Society of Gene Therapy. January, 2009
41. A Novel Compound for the Treatment of Allergy and Autoimmune Disease Oral Presentation, AAAI, March 13-17, Washington, DC. 2009. Journal of Allergy and Clinical Immunology January, 2009
42. Knowledge, attitudes, practices and willingness to participate in HIV vaccine trials among urban residents West Africa, 2005‚2009. P15-07. AIDS Vaccine 2009. Paris, France. 19:22 October 2009. Retrovirology, Volume 6 Suppl 3 January, 2009
43. Protecting Our Next Generation Immunology of Vaccines. January, 2009
44. Immunoinformatics: How to design more effective vaccines and therapeutic proteins. Regulatory Scientific Research Seminar Series, Centre for Biologics Research January, 2009
45. A Novel Compound for the Treatment of Allergy and Autoimmune Disease. Oral Presentation, AAAI, March 13-17, Washington, DC. 2009. Journal of Allergy and Clinical Immunology January, 2009
46. IgG-Derived Tregitope Peptides Suppress T Cell Responses in Vitro and in Vivo 50th annual Meeting of the American Society for Hematology December, 2008
47. IgG-Derived Tregitope Peptides Suppress T Cell Responses in Vitro and in Vivo Oral Presentation 677, 50th annual Meeting of the American Society for Hematology December, 2008
48. De-Immunization of Human Factor VIII: Identification of Epitopes in the C2 Domain. Poster 1030, 50th annual Meeting of the American Society for Hematology. December 6-10, 2008. San Francisco, California. December, 2008
49. Immunogenicity Problems: A Paradigm Shift? 19th annual Antibody Engineering: Immunotherapeutics for the 21st Century December, 2008
50. EpiMatrix: Tool for Accelerated Epitope Selection and Vaccine Design 2nd Global Vaccine Congress December, 2008
51. A Venn vaccine: selection and validation of vaccinia-variola-conserved epitopes. 2nd Global Vaccine Congress December, 2008
52. Rapid development and validation of a T-cell epitope-based Tularemia vaccine for F. Tularensis. 2nd Global Vaccine Congress, Boston Massachusetts December, 2008
53. The GAIA HIV vaccine progress report: broad recognition of class I and II-restricted epitopes and in vivo studies 2nd Global Vaccine Congress December, 2008
54. Role of Tregs: Insights for the design of improved Hepatitis C vaccine. 2nd Global Vaccine Congress, Boston Massachusetts December, 2008
55. Relevance of T cell epitopes, effector T cells and regulatory T cells to the development of immunogenicity, and the accuracy of T cell epitope analysis for immunogenicity screening EMEA (European Medicines Agency). October, 2008
56. A call to humoral and cellular arms: A case for enlisting cognate T cell help to develop broad-spectrum vaccines against influenza Sixth World Congress on Vaccines, Immunisation and Immunotherapy, 23-25 September 2008: Milan September, 2008
57. Designing Personalized Vaccines for the 21st Century Sixth World Congress On Vaccines, Immunization and Immunotherapy September, 2008
58. Computer-Driven Vaccine Design: From Concept to Reality Vaccine Development September, 2008
59. The GAIA Vaccine Progress Report: Broad Recognition of Class I and II-Restricted Epitopes and in vivo Studies Vaccine Development conference September, 2008
60. Immunogenicity of Biologics Inflammation Research Association's 15th International Conference September, 2008
61. Increased HIV and STI testing in Bamako, Mali using a push/pull intervention. Poster CDC0368 accepted to the CD-ROM of the XVII International AIDS Conference August, 2008
62. High Throughput validation of predicted T-cell epitopes in F. Tularensis: The development of a novel T-cell epitope-based Tularemia vaccine Rhode Island Research Alliance Symposium on June 3, 2008 at the RI Convention Center. June, 2008
63. Epitope Driven GAIA HIV Vaccine Development Vaccine Technology II June, 2008
64. IgG Tregitopes and AITD-ASATI: Antigen specific tolerance induction in Autoimmune Thyroid Disease Rhode Island Research Alliance Symposium on June 3, 2008 at the RI Convention Center. June, 2008
65. Positive Prediction of Immunogenic Vaccine Candidate Epitopes and Progress on the Development of an IDV Vaccine for H. pylori Eleventh Annual Conference on Vaccine Research, National Foundation for Infectious Diseases May, 2008
66. Epitope-based Immunome-derived Vaccines: A Strategy for Improved Design and Safety Eleventh Annual Conference on Vaccine Research May, 2008
67. Updated results from ongoing work on the GAIA HIV Vaccine: Broad Recognition of class I and II-restricted epitopes and in vivo studies Eleventh Annual Conference on Vaccine Research, National Foundation for Infectious Diseases. May, 2008
68. HIV Vaccines: Time for a New Vision Voices from the Vanguard Lecture Series April, 2008
69. Incarcerated Women and HIV HIV in Women Conference; Texas-Okla. AETC Dallas April, 2008
70. Rational design and regulatory issues of immunotherapeutic vaccines Vaccine and Immunotherapy Technologies, Sir Mark Oliphant Conference April, 2008
71. IgG Tregitopes and AITD-ASATI: Antigen Specific Tolerance Induction in Autoimmune Thyroid Disease LJ De Groot presented poster at the meeting March, 2008
72. Moving Computer Driven Vaccine Design From In Silico to In Vivo Nature Biotechnology Winter Symposium January, 2008
73. A Novel Model of IVIG Immunosuppression: Activation of Natural Regulatory T cells by IgG-Derived Peptides FASEB. The FASEB Journal January, 2008
74. A Novel Model of IVIG Immunosuppression: Activation of Natural Regulatory T cells by IgG-Derived Peptides Keystone Symposium Tolerance in Transplantation and Autoimmunity January, 2008
75. Hand of Hope (Here Bolo): A Peer Education Tool for Low Literacy Settings GAIA Mali, ASACOMSI, Millennium Villages Project, University of Bamako, GAIA Vaccine Foundation (USA). Poster and Abstract A-072-0179-00876 International AIDS Conference January, 2008
76. Updated results from ongoing work on the GAIA HIV Vaccine: Recognition of class I and II-restricted epitopes in Bamako, Mali and Providence CROI meeting January, 2008
77. Immunogenicity in vivo: Proof-of-concept study of an immunome-derived smallpox vaccine NFID Eleventh Annual Meeting on Vaccine Research. National Foundation for Infectious Diseases January, 2008
78. New Approaches to Immunogenicity: Screening, Reengineering and Modulation. Antibodies Europe November, 2007
79. De-immunization of protein therapeutics Crossroad of Biotechnology 12th edition at the Biotechnology Research Institute of the National Research Council (NRC-BRI), June, 2007
80. Cutting Edge: Screening and Reengineering Biological Therapeutics Track: Drug Discovery and Development, Bio 2007 June, 2007
81. De-Immunization of Protein Therapeutics Crossroad of Biotechnology, Montreal, Canada June, 2007
82. Targeted PCR confirmation of vaccine components conserved between human and mouse-adapted strains of H. pylori American Gastro Association meeting May, 2007
83. Update on the GAIA HIV Vaccine 3ème Journees VIH/SIDA de Bamako January, 2007
84. Moving Computer Driven Vaccine Design in silico to in vivo Nature Biotechnology Winter Symposium, January, 2007
85. Upregulating and Downregulating Immunity from the T cell Perspective University of Rhode Island Department of Cellular and Molecular Biology January, 2007
86. Potential immunogenicity of predicted epitopes conserved between human and mouse-adapted strains of H. pylori 10th Annual Conference on Vaccine Research January, 2007
87. Further progress on the immunome-based DNA prime / Peptide boost smallpox vaccine: Results from in vivo immunogenicity assays 10th Annual Conference on Vaccine Research January, 2007
88. Protective effect of an epitope driven vaccine against F. tularensis: Survival of aerosol-challenged mice. Oral presentation 10th Annual Conference on Vaccine Research January, 2007
89. Potential Barriers to an HIV Vaccine Trial in Bamako Mali. 3ème Journees VIH/SIDA de Bamako January, 2007
90. Survey of Knowledge, attitudes and practices related to HIV and HIV Vaccines in Urban Markets, Bamako Mali 3ème Journees VIH/SIDA de Bamako January, 2007
91. Applied Epitope Mapping: Progress report on Epitope-driven BioDefense Vaccine Development for Smallpox and Tularemia International Immunomics Society Meeting October, 2006
92. High Throughput Validation of Predicted T-cell Epitopes in F. Tularensis: The Development of a Novel T-cell Epitope Based Tularemia Vaccine Poster Abstract, 32nd Annual New England Immunology Conference October, 2006
93. Elicitation of robust T cell responses in HLA DRB1*0101 transgenic mice by MHC class II compartment-targeted and untargeted HIV T helper multiepitope molecular constructs Paper Number: 441.00. AIDS Vaccine 2006, Amsterdam August, 2006
94. Knowledge, Attitudes, and Practices study in marketplaces of Bamako, Mali to inform the design of HIV vaccine trials. Paper Number: 231.00. AIDS Vaccine 2006, Amsterdam August, 2006
95. 2006 progress update on the GAIA HIV Vaccine: Broad coverage by HLA alleles and Geographic Location, Optimization of HIV Immunogens in Pre Clinical Studies Paper Number: 438.00. AIDS Vaccine 2006, Amsterdam August, 2006
96. progress update on the GAIA HIV Vaccine: Broad coverage by HLA alleles and Geographic Location, Optimization of HIV Immunogens in Pre Clinical Studies. Paper Number: 438.00. AIDS Vaccine 2006, Amsterdam August, 2006
97. High Throughput validation of predicted T-cell epitopes conserved between Variola and Vaccinia: Development of a novel immunome based Smallpox vaccine Poster presentation at the 6th Annual Meeting of the Federation of Clinical Immunology Societies June, 2006
98. Women and HIV Overview Incarcerated Women and HIV June, 2006
99. High Throughput validation of predicted T-cell epitopes in F. Tularensis: The development of a novel T-cell epitope based Tularemia vaccine. Poster presentation at the 6th Annual Meeting of the Federation of Clinical Immunology Societies June, 2006
100. Vaccine Development from Soup to Nuts - the GAIA HIV Vaccine Case Study Brown Medical School Infectious Disease Division Lecture Series April, 2006
101. Sugar or Splice: New approaches to solve the Immunogenicity Problem Cell Culture Engineering X – Whistler Resort, Vancouver CA April, 2006
102. Cancer Grand Rounds “Immunoengineering of Cancer Vaccines and Therapeutics - Recent developments.” Rhode Island Hospital April, 2006
103. Knowledge, Attitudes, and Practices study in marketplaces of Bamako, Mali to inform the design of HIV vaccine trials. World AIDS Conference January, 2006
104. Update on De-immunzation Studies (DeFT). CBER Brown Bag Seminar January, 2006
105. Update on De-immunization Studies (DeFT) FDA-CDER, HFD-122 January, 2006
106. Class II HLA-binding peptides in C3d: possible role as co-signal 2 in B-cell help American Association of Immunologists January, 2006
107. Provider perspectives about the standard of HIV care in correctional settings and comparison to the community standard of care: How do we measure up? World AIDS Conference. Toronto January, 2006
108. Elicitation of robust T cell responses in HLA DRB1*0101 transgenic mice by MHC class II compartment-targeted and untargeted HIV T helper multiepitope molecular constructs Paper Number: 441.00. AIDS Vaccine 2006, Amsterdam. January, 2006
109. Knowledge, Attitudes, and Practices study in marketplaces of Bamako, Mali to inform the design of HIV vaccine trials World AIDS Conference. Toronto January, 2006
110. High Throughput validation of predicted T-cell epitopes conserved between Variola and Vaccinia: Development of a novel immunome based Smallpox vaccine, 9th Annual Conference on Vaccine Research, National Foundation for Infectious Diseases January, 2006
111. GAIA HIV Vaccine Development: Optimization of the Immunogens in Pre Clinical Studies Oral Abstract, AIDS Vaccine 2005 (poster September, 2005
112. Mapping and confirming highly conserved HLA B7-restricted epitopes for the GAIA vaccine Poster Abstract AIDS Vaccine 2005; 09/05, Montreal September, 2005
113. T-helper Multiepitope HIV-1 Vaccine Constructs Engineered by Computer-Assisted Selection and Design elicit broad T cell responses in vivo in the presence of IL-15 Poster Abstract AIDS Vaccine 2005, 09/05, Montreal September, 2005
114. presentation of Confirmed A3 supertype T cell Epitopes selected for the GAIA Cross-Clade HIV Vaccine Poster Abstract AIDS Vaccine September, 2005
115. Expanded T cell response repertoire achieved by a HLA A2 multi-epitope cross-clade HIV vaccine in the presence of IL-15 Poster Abstract. AIDS Vaccine 2005. 09/05, Montreal September, 2005
116. Potential Barriers to an HIV Vaccine Trial in Bamako Mali Poster Abstract, AIDS Vaccine 2005. 09/05, Montreal September, 2005
117. Women and HIV Overview, Mother to Child Transmission Prevention. Incarcerated Women and HIV June, 2005
118. What can Therapeutics learn from Vaccines FDA Science Forum April, 2005
119. Deimmunization - the DeFT (T cell epitope mapping) approach. FDA-CDER, HFD-122 March, 2005
120. What’s New? From Genomics to Vaccine Design; From Immunome to Vaccine 2nd International Immunomics Symposium March, 2005
121. T epitope Revelations: Antigen Discovery (Vaccines) and De-Immunization (Therapeutics) Salk Institute, San Diego March, 2005
122. TB Vaccine Development Update 9th Annual Meeting of the North American Region of the International Union Against Tuberculosis and Lung Disease February, 2005
123. Computational methods and in vitro testing to identify novel epitopes for a therapeutic EBV vaccine Fourth World Congress on Vaccines and Immunization, Tskukuba Science City October, 2004
124. In silico and in vitro evaluation of cross-conserved T cell epitopes for Japanese encephalitis virus and West Nile virus Accepted, (Poster P4) Fourth World Congress on Vaccines and Immunization, Tskukuba Science City October, 2004
125. T-cell epitopes conserved between variola and vaccinia: Prediction and confirmation. (Poster P5) Fourth World Congress on Vaccines and Immunization, Tskukuba Science City October, 2004
126. From Immunome to Vaccine: the Epitope-Driven Vaccine Approach Fourth World Congress on Vaccines and Immunization, Tskukuba Science City /Tokyo, Japan September, 2004
127. Immunogenic consensus sequence T cell epitopes for a cross-clade HIV vaccine. Fourth World Congress on Vaccines and Immunization September, 2004
128. The epitope-driven vaccine approach Fourth World Congress on Vaccines and Immunization, Tskukuba Science City /Tokyo, Japan September, 2004
129. Developing an Epitope-Based HPV Vaccine Fourth World Congress on Vaccines and Immunization September, 2004
130. From Immunome to Vaccine Fourth World Congress on Vaccines and Immunization, Tskukuba Science City /Tokyo, Japan September, 2004
131. Elicitation of de novo T-cell responses in mice immunized with an multi HIV-1 epitope cross-clade DNA vaccine AIDS Vaccine 2004, Lausanne August, 2004
132. Developing a Immunogenic Consensus Sequence T cell Epitopes for the GAIA Cross-Clade HIV Vaccine The National Foundation for Infectious Diseases: Eight Annual Conference on Vaccine Research May, 2004
133. Prediction and Confirmation of Novel Smallpox Ligands Based on Conserved T cell Epitopes from the Vaccinia and Variola Genomes. The National Foundation for Infectious Diseases: Eighth Annual Conference on Vaccine Research May, 2004
134. The AIDS Pandemic Brown University 135th Commencement Forum May, 2004
135. AIDS Vaccines and Prevention Provoking Hope, A Brown University AIDS Symposium April, 2004
136. From Genome to Vaccine University of Rhode Island. BRIN seminar April, 2004
137. New Immunoinformatics Approaches to Emerging Infectious Diseases Boston University, Bioinformatics program April, 2004
138. From immunome to vaccine: the epitope-driven vaccine approach Singapore Immunoinformatics Symposium. From databases to vaccines March, 2004
139. Women and HIV Overview, Mother to Child Transmission Prevention, and HIV: African Realities. Incarcerated Women and HIV. Half-day seminar March, 2004
140. Genome-derived Vaccines Southern Center for Vaccine Development. University of Texas Medical Branch, Galveston, Texas March, 2004
141. The Economics of AIDS and HIV Vaccine Development International Affairs Committee, Providence Rhode Island. March, 2004
142. From immunome to vaccine: the epitope-driven vaccine approach 1st International Immunoinformatics Symposium - Immunology meets Bioinformatics. RIKEN (The Institute of Physical and Chemical Research), Yokohama Institute, Genomic Sciences Center (GSC), Bioinformatics Group. Session on Computer-aided vaccine and adjuvant development. Yokohama, Japan (Scientific Advisory Committee). February, 2004
143. Forgotten Many: HIV –seropositive Women in Prison, IDU and Adolescents Emerging Issues in the Management of HIV Disease in Women January, 2004
144. HIV Vaccine for all Clades Rencontre des Specialistes VIH/SIDA a Bamako. GAIA Vaccine Foundation / Fondation Merieux January, 2004
145. Providence, USA: Confirmation of immunogenic consensus sequence T cell Epitopes for the GAIA cross-clade HIV vaccine Abstract no. ThPeA6995 The XV International AIDS Conference January, 2004
146. Bamako, Mali: confirmation of immunogenic consensus sequence T cell Epitopes for the GAIA Cross-Clade HIV Vaccine Abstract no. ThPeA6996 The XV International AIDS Conference January, 2004
147. Accelerating Vaccine Design: new in insilico epitope mapping methods Animal Research Service (ARS) Immunology Research Workshop Bethesda MD. December, 2003
148. What Corrections-Based Staff Need to Know Prevention and Treatment of Infectious Disease in Corrections December, 2003
149. Immununomodulation: In silico prediction and in vitro confirmation Immunogenicity testing for Protein-based therapeutics November, 2003
150. From Genome to Vaccine, A story about Microsoft, Motifs, and Molecules Colloquium Series, Biology Department at Rhode Island College November, 2003
151. Infectious and Transmissible Diseases in Correctional Settings. HEPP Report pre-conference symposium October, 2003
152. From Genome to Vaccine: Faster, Better Design of Vaccines and Therapeutic Products through Immunoinformatics Fall Connecticut Nanotech Initiative Conference October, 2003
153. Rapid Vaccine Design for Emerging Infections; EpiVax-Brown University Collaborations on SARS, WNV, Smallpox, WNV, TB and HIV Rhode Island Department of Public Health September, 2003
154. TB vaccine development: practical design and implementation World Vaccine Congress, Lyon September, 2003
155. From TB Genome to Vaccine TB Vaccines for the World- TBV 2003, Montreal Marriott Chateau Champlain, Montreal, Canada. September, 2003
156. Epitope-Driven TB DNA Vaccines: An Immunoinformatics Approach TB Vaccine 2003. Montreal, Canada. September, 2003
157. Towards Developing an Epitope-Based HPV Vaccine. Poster Presentation. Microbial Pathogenesis and Host Response. Cold Spring Harbor September, 2003
158. Using Computational methods and in vitro testing to identify novel epitopes in Epstein Barr Virus Cold Spring Harbor Laboratory Microbial Pathogenesis & Host Response September, 2003
159. Texas MiniFellowship Correctional HIV Providers September, 2003
160. The GAIA HIV Vaccine: Vaccine for the World HIV Vaccines: Design, Potency and Delivery. The Knowledge Foundation. Conference on HIV Vaccines June, 2003
161. In Silico Prediction of Immunogenicity State of the art Analytical Methods for the Characterization of Biological Products and Assessment of Comparability Natcher Building, National Institutes of Health Bethesda, Maryland June, 2003
162. Prototype Multi-Epitope DNA Vaccine Design for HIV. The National Foundation for Infectious Diseases: Sixth Annual Conference on Vaccine Research May, 2003
163. Tripathi Knowledge, Attitudes, Practice survey of an HIV Vaccine in Bamako Mali. Oral Presentation. Undergraduate International Research Conference on Global Public Health. May, 2003
164. Prototype Multi-epitope DNA Vaccine Design Oral Presentation Undergraduate International Research Conference on Global Public Health May, 2003
165. Developing an Immunogenic Consensus Sequence T cell Epitopes for the GAIA Cross-Clade HIV Vaccine Sixth Annual Conference on Vaccine Research/NFID National Foundation for Infectious Diseases May, 2003
166. Analyzing Mycobacterium tuberculosis proteomes for candidate TB vaccine epitopes. The National Foundation for Infectious Diseases: Sixth Annual Conference on Vaccine Research May, 2003
167. TB Vaccines: How long do we need to wait? Tuberculosis Education Day 2003 May, 2003
168. From genome to vaccine: epitope mapping and vaccine design tools Computational Molecular Biology Series. Brown University March, 2003
169. Adolescent STDs: The situation with HIV and update on the GAIA HIV Vaccine Pediatric Grand Rounds, Hasbro and Rhode Island Hospital. Pediatric Grand Rounds February, 2003
170. Post Exposure Prophylaxis of HIV infection HIV Minifellowship. University of Texas Medical Branch February, 2003
171. Use of Bioinformatics and Molecular Biology for Mycobacterium tuberculosis Antigen Keystone Symposium January, 2003
172. Harnessing the ‘Immunome’ Phacilitate Vaccine Forum November, 2002
173. Medical Update on Opening Pandora’s Box: Is there Hope after AIDS? 2002 Rhode Island Medical Women's Association's Educational Session November, 2002
174. Real Life Examples: Managing Infectious Disease in Corrections NCCHC annual conference, HEPP Preconference Symposium October, 2002
175. Epitope mapping and vaccine design tools Novartis Foundation Symposium No.254 Immuno‑informatics: Bioinformatic strategies for better understanding of immune function. October, 2002
176. Analyzing the Mycobacterium tuberculosis proteomes for candidate TB vaccine epitotopes. 4th World TB Congress, Marriot Hotel June, 2002
177. Immunogenicity of Peptides Derived from S. mutans GBP-B International Association of Dental Researchers (IADR) /2002, SanDiego abstract_219. June, 2002
178. Analyzing Myobacterium Tuberculosis Proteomes for Candidate TB Vaccine Epitopes. S36: The National Foundation for Infectious Diseases: Fifth Annual Conference on Vaccine Research May, 2002
179. New Uses for Licensed Vaccines: Evaluation of the Japanese Encephalitis Virus Vaccine and the NY99 West Nile Virus Genomes for Cross-reactive T Cell Epitopes S35: The National Foundation for Infectious Diseases: Fifth Annual Conference on Vaccine Research May, 2002
180. Analyzing Myobacterium Tuberculosis Proteomes for Candidate TB Vaccine Epitopes. Fifth Annual Conference on Vaccine Research, Baltimore May, 2002
181. New Uses for Licensed Vaccines: Evaluation of the Japanese Encephalitis Virus Vaccine and the NY99 West Nile Virus Genomes for Cross-reactive T Cell Epitopes Oral presentation S35: The National Foundation for Infectious Diseases: Fifth Annual Conference on Vaccine Research May, 2002
182. Building Vaccines from Immunogenic Consensus Sequences Oral Presentation S29: The National Foundation for Infectious Diseases: Fifth Annual Conference on Vaccine Research May, 2002
183. HIV Management of Incarcerated Women Federal Bureau of Prisons Annual Nursing Conference April, 2002
184. From Genome to T Cell Epitope-Driven Vaccine Design Australian Society for Immunology Canberra Australia December, 2001
185. TB Genome to Vaccine (Bringing a Genome Derived TB Vaccine to Phase I Trials). Foundation Vaccine 2001 Conference, Renaissance Conference Cente November, 2001
186. Developing an Epitope-Driven Cross-Clade HIV Vaccine using Bioinformatics Harvard HIV Vaccine Trial Unit, Harvard Medical School November, 2001
187. HIV infection in Incarcerated Women University of Texas Medical Branch October, 2001
188. Computational Algorithms to Predict T cell Immunogenicity Conference on Immunogenicity of Therapeutic Biological Products, Lister Hill Auditorium, NIH, Bethesda MD October, 2001
189. Epitope-Driven Vaccines for TB and HIV infection Grand Rounds, Lemuel Shattuck Hospital, Boston MA August, 2001
190. Computational methods for mapping T cell epitopes in the TB proteome: A streamlined approach to vaccine design U.S.-Japan Joint Tuberculosis/Leprosy Conference July, 2001
191. Epitope-Driven HIV Vaccine Development Division of AIDS June, 2001
192. From Genome to T cell: Bioinformatics and Vaccine Design Lecture at Center for Vaccine Development. ( Myron M. Levine, M.D., D.T.P.H. Director). University of Maryland School of Medicine June, 2001
193. HIV Behind Bars CME accredited course for Correctional HIV providers June, 2001
194. Computational methods for mapping T cell epitopes: A streamlined approach to vaccine design FOCIS Annual Meeting May, 2001
195. Designing an HIV world clade vaccine using bioinformatics-based approach Second International Conference on Vaccine Development and Immunotherapy in HIV May, 2001
196. Building Vaccines from Immunogenic Consensus Sequences. Oral Presentation S29: The National Foundation for Infectious Diseases: Fifth Annual Conference on Vaccine Research May, 2001
197. Cross-Clade Conservation of HIV-1 CTL Epitopes in the Aidsvax® and Aventis CP205™ Vaccines National Foundation for Infectious Diseases annual Vaccine conference April, 2001
198. Cross-Clade CTL in Thai HIV-Infected Subjects. 8th Conference on Retroviruses and Opportunistic infections February, 2001
199. World Clade Vaccine Design: Selection and Confirmation of Conserved HIV-1 CTL Epitopes Using a Bioinformatics Approach 8th Conference on Retroviruses and Opportunistic infections February, 2001
200. Rapid Determination of candidate HLA B*07- restricted CTL epitopes from the West Nile Virus NY99 genome NFID Fourth Annual Conference on Vaccines, Arlington VA 2001. Oral presentation Poster presentation P17. January, 2001
201. From Genome to T Cell: Epitope-Driven TB Vaccine Design Molecular and Cellular Aspects of Tuberculosis Research in the Post-Genome Era. January, 2001
202. Cross-Clade Conservation of HIV-1 CTL Epitopes in the Aidsvax® and Aventis CP205™ Vaccines NFID Fourth Annual Conference on Vaccines, Arlington VA 2001. Oral presentation S17 January, 2001
203. Genomics and Vaccinomics University of Richmond, VA December, 2000
204. Scanning the TB Genome for DNA Vaccine Epitopes Sequella TB Vaccine Conference November, 2000
205. TB pathogenesis, Vaccination, and Treatment update Anesthesiology Rounds, Kent Hospital November, 2000
206. Genomic Approaches for Identifying Vaccine Candidates – Bioinformatics and Predictive Algorithms Special meeting on Otitis Media: New Approaches for Analysis, Treatment and Prevention November, 2000
207. From Genome to Vaccine: Bioinformatics and Vaccine Design Technologies Seminar, Center for Biomedical Inventions and Department of Internal Medicine & Cardiology University of Texas-Southwestern Medical Center at Dallas October, 2000
208. From Genome to T cell: In silico predictions, in vivo veritas. Invited speaker. Symposium on Genomics and Vaccinology National Foundation for Infectious Diseases annual Vaccine conference. April, 2000
209. Prisoner Research CCG Scientific Agenda Subcommittee conference call April, 2000
210. Informatics Approaches to Vaccine Design Vaccines and Immunotherapeutics in the Third Millennium CSIRO, Lorne Australia March, 2000
211. Scientific Working Group on TB World Health Organization. (Dr. Paul Nunn, organizer), 02/00 Geneva, Switzerland February, 2000
212. HLA A2 Restricted, CD8 Dependent Ctyotoxic T cell response to mycobacterial superoxide dismutase Microbial Pathogenesis and Host Response, Cold Spring Harbor January, 2000
213. Prospective Identification of MHC Ligands and CTL Epitopes from HIV Proteins using Bioinformatics 7h Conference on Retroviruses and Opportunistic infections January, 2000
214. Use of the plasmid pRc/CMV-HBs(S) as a vector for an epitope-based DNA vaccine against Mycobacterium tuberculosis Molecular Approaches to Vaccines Meeting, Cold Spring Harbor Laboratory December, 1999
215. Successful identification of novel HIV-2 epitopes and a single “cross-reactive” HIV-1/HIV-2 CTL epitope using a bioinformatics approach Molecular Approaches to Vaccines Meeting, Cold Spring Harbor Laboratory December, 1999
216. Developing a World Clade HIV Vaccine using a Bioinformatics Approach Molecular Approaches to Vaccines Meeting, Cold Spring Harbor Laboratory December, 1999
217. Towards developing an HIV 1 vaccine for India: Computer driven prediction and analysis of CTL epitopes Molecular approaches to Vaccine Design. Cold Spring Harbor Laboratory December, 1999
218. Use of the plasmid prc/CMV-HBS(S) as a vector for an epitope-based vaccine against Mycobacterium tuberculosis Molecular approaches to Vaccine Design. Cold Spring Harbor Laboratory December, 1999
219. Management of HIV in Correctional Facilities Central Florida Receiving Facility, Orlando Florida June, 1999
220. HIV Vaccine Development 6th conference on Retroviruses and Opportunistic Infections, Chicago, Illinois February, 1999
221. Bio informatics approaches to Vaccine Development for TB and HIV DASTLR, Center for Disease Control and Prevention, Immunology, (Dr. Janet McNicholl, host), Atlanta Georgia February, 1999
222. Bio informatics approaches to Vaccine Development for HIV Emory Center for Vaccine Research, (for the CFAR program, Dr. Mark Feinberg, host), Atlanta, Georgia February, 1999
223. Breaking the Wall of Silence: Women, HIV/AIDS, and the Prison System Policy Action Network Briefing at the US Senate, Russell Office Building for Senate Staffers February, 1999
224. From Genome to T Cell: Searching for Agretopes poster and abstract, Second Annual Vaccine meeting (ASM, NIAID, NFID January, 1999
225. From Genome to T Cell: Searching for Agretopes Microbial Genomes conference, sponsored by the Institute for Genomic Research (TIGR) (Dr. Clare Fraser, host), Chantilly VA, January, 1999
226. Epitope Predictions and Vaccine Testing EEC committee on the Ethical and Legal Applications of Vaccines (ELAV, (R. Whalen, host), Paris, France January, 1999
227. Genome to T Cell: Epitope-Driven Vaccine Design Abstract and oral presentation, Microbial Genomes Conference, Chantilly January, 1999
228. Designing and Assessing HIV Vaccines for Cross-Clade Immunogenicity using Bio-informatics Poster at the 6th conference on Retroviruses and Opportunistic Infections January, 1999
229. HIV Management in the Prison Setting: An Update AIDS Education and Training Center and Correctional Medical Service, Newark, New Jersey December, 1998
230. Management of the HIV infected inmate Delaware AIDS Council Annual Meeting, Wilmington Delaware November, 1998
231. What's different about Women living with HIV in Corrections National Commission on Correctional Health Care November, 1998
232. V3 loop immunoreactivity and diversity among HIV-1 isolates from the Philippines. Int Conf AIDS July, 1998
233. HIV infection among incarcerated women New England Medical Center series for HIV infected Women June, 1998
234. HLA-A11 Cytotoxic T Lymphocyte Epitopes in HIV-1 env Subtype E poster and oral presentation at the International AIDS Conference, Geneva June, 1998
235. Matrix based prediction of MHC binding peptides: the TIGR/EpiMatrix website, reagent for TB research Conference on TB: Molecular mechanisms and Immunopathogenesis, Keystone, Colorado April, 1998
236. TB and HIV vaccine development Infectious Disease Conference (Dr. Jennifer Daly, Host) TB/HIV vaccine development, Worcester MA March, 1998
237. Cytotoxic T cell activity against HIV-tat in HIV infected children HIV Pathog Treat Conf March, 1998
238. Construction of a DNA vaccine for TB containing promiscuous T cell epitopes First Annual Vaccine meeting (ASM, NIAID, NFID) January, 1998
239. Towards Developing an HIV-1 Vaccine for India: Computer-Driven Prediction and Analysis of Cytotoxic T-Lymphocyte (CTL) Epitopes First Annual Vaccine meeting (ASM, NIAID January, 1998
240. HIV infection among incarcerated women: Clinical Care, New England School of Law, Symposium on the Treatment of Women Prisoners Boston January, 1998
241. State of the Art Workshop, Living with HIV behind prison walls: perspectives from a patient and her physician Women and HIV infection Conference October, 1997
242. Epitope Predictions for TB vaccine development Global Tuberculosis Programme for Vaccines and Immunization/Vaccine Research and Development conference," Definition of Strategies for an optimal use of Information resulting from Mycobacterial genome sequencing" at the World Health Organization Headquarters (Dr. John Foulds, organizer), Geneva September, 1997
243. Computer algorithms for TB vaccine design Pasteur Institute (Dr. Brigitte Gicquel, host), Paris, France September, 1997
244. Symposium on Immunogenicity of Recombinant Human Proteins. EpiMatrix: Prediction of MHC ligands Genentech (Dr. Gene Koren, host), South San Francisco March, 1997
245. Care and Treatment in Prisons and Jails (Panel #406) 9th Annual AIDS Update Conference, San Francisco, California March, 1997
246. Intensive workshop on HIV Behind Bars: Providing Education, Advocacy, Care and Services (Intensive workshop #1) 9th Annual AIDS Update Conference, San Francisco, California March, 1997
247. Computer-driven Design of new HLA-based vaccines for HIV Partners AIDS Research Center (Dr. Bruce Walker, host), Massachusetts General Hospital February, 1997
248. Matrix-based definition of MHC ligands from primary HIV-1 and HIV-2 protein sequences: the EpiMatrix/HIV Web Site Keystone HIV/AIDS Pathogenesis meeting January, 1997
249. Prediction and validation of HLA-B7 restricted CTL epitopes based on upon autologous HIV-1 sequences Keystone HIV/AIDS Pathogenesis meeting January, 1997
250. Corrections Responds to HIV disease among Incarcerated Women Correctional HIV Consortium Winter Update January, 1997
251. HLA-A11 Cytotoxic T Lymphocyte Epitopes in HIV-1 env Subtype E Keystone HIV/AIDS Pathogenesis meeting January, 1997
252. Clusters of published HIV-1 CD8+ CTL epitopes: peptide diversity and HLA-dependent population coverage Annual Convention of the Philippine Society for Biochemistry and Molecular Biology December, 1996
253. HIV and incarcerated women: Risks, Models of Care APHA panel on Prisons and Jails (Socialist Caucus) APHA meeting, New York City November, 1996
254. Second Generation HIV/AIDS behind Bars NCCHC conference October, 1996
255. EpiMatrix algorithm, reagent for HIV vaccine research Molecular Approaches to Vaccines for Infectious Diseases, Cold Spring Harbor Laboratory, New York September, 1996
256. Designing a subunit vaccine for M. tuberculosis using a novel epitope prediction algorithm: Gambian responses to population weighted vs. unweighted peptides Molecular Approaches to the Control of Infectious Diseases Cold Spring Harbor Laboratory September, 1996
257. The predicted utility of several phase III HIV-1 vaccines for selected world populations Molecular Approaches to the Control of Infectious Diseases Cold Spring Harbor Laboratory September, 1996
258. Population-dependent prediction of CTL epitopes for HIV clades using a computer-driven algorithm International AIDS conference July, 1996
259. Computer Algorithms for HIV Vaccine Development HIV Research Unit, (Drs. Brigitte Autran, Anne Hosmalin, hosts) Hôpital Pitié-Salpêtrière, Paris, France June, 1996
260. Comstock Conference on Epidemiology and Control of TB: Vaccines & TB Control Baltimore Maryland; organized by Phil Hopewell, UCSF June, 1996
261. Identification of Phylogenetically conserved clusters of published and predicted HIV 1 CD8+ CTL epitopes in geographically diverse populations International Infectious Disease society meeting June, 1996
262. Effective Interventions to prevent HIV in Correctional Facilities Prevention Summit, HIV Prevention Planning May, 1996
263. Matrix based prediction of MHC binding peptides Division of AIDS Spring workshop on HIV Variability and Cellular Immune Recognition, Bethesda, Maryland April, 1996
264. Sexual abuse and HIV Risk taking Planned Parenthood April, 1996
265. Epitope prediction for HIV vaccine development Harvard AIDS Institute, HIV Vaccines for Developing Countries: Antigen Design, Boston, Massachusetts April, 1996
266. Prisons: Inside/Out Departments of Legal Studies, Political Science, and Women's Studies, UMass Amherst. Invited speaker, panel on Economics of Prison and Sentencing Issues March, 1996
267. CTL workshop: Computer driven epitope prediction for HIV vaccine development, NCDVG conference on HIV Vaccine development CTL workshop. (Jim Bradac, DAIDS Program Officer). Bethesda, Maryland February, 1996
268. Computer Algorithms for TB and HIV Vaccine Development Department of Immunology (Dr. David McMurray, host), Texas A & M University, College Station Texas January, 1996
269. Computer Algorithms for Cancer Vaccine Development Wistar Institute (Dorothee Herlyn, host), Philadelphia, Pennsylvania January, 1996
270. HIV risk behaviors and HIV related morbidity in a cohort of incarcerated women in Massachusetts International AIDS Conference, Vancouver January, 1996
271. HIV infection in Incarcerated Women: Priorities for Research Clinical AIDS Research; PRIM&R, Boston MA November, 1995
272. Evolution of HIV Quasi Species: Response to Immune Pressure? Diamond AIDS Research Center (Dr. Rick Koup, host), New York City, NY November, 1995
273. Reducing the risk of tuberculosis transmission in the prison setting through the use of environmental controls: A cost benefit analysis National Commission on Correctional Health Care 19th conference November, 1995
274. Health services for HIV seropositive incarcerated women: The Framingham model oral presentation at the National Commission on Correctional Health Care 19th conference November, 1995
275. The Framingham model and Health Services for HIV seropositive women National Correctional Health Care conference November, 1995
276. Reducing the risk of tuberculosis transmission in the prison setting through the use of environmental controls (HEPA filters and UV lights), Correctional Health Care conference November, 1995
277. Sexual Abuse and HIV Risk Taking among Incarcerated Women National Drug Abuse Treatment Association conference November, 1995
278. Computer Algorithms for TB Vaccine Development Public Health Research Institute (Dr. Marilla Gennaro, host), New York, October, 1995
279. Risks for HIV infection among Incarcerated Women Yale AIDS Colloquium Series October, 1995
280. TB in Prisons New England HIV in Prisons Conference October, 1995
281. Computer Algorithms for Vaccine Development Biology and Technology Seminar: Boston University (Dr. Charles Delisi, host), Boston MA September, 1995
282. A novel algorithm for the efficient identification of T cell epitopes: prediction and testing of candidate TB vaccine peptides in genetically diverse populations Cold Spring Harbor meeting on Vaccines for Infectious Diseases, September, 1995
283. Use of pediatric tuberculosis infection as a marker of tuberculosis transmission in communities in Providence Lancet Tuberculosis Conference September, 1995
284. Algorithms for mycobacterial vaccine development International symposium on Bovine TB in Animals and Human Beings, USDA/NIAID, NIH May, 1995
285. Reducing the risk of tuberculosis transmission in the prison setting through the use of environmental controls including UVG Irradiation and HEPA filtration Lancet Tuberculosis Conference May, 1995
286. Co-infection with M. tuberculosis and HIV-1 in Providence American Thoracic Society Meeting May, 1995
287. HIV infection in Women Harvard AIDS Institute, Changing Times, Changing Strategies, AIDS in New England April, 1995
288. Childhood sexual abuse increases vulnerability to HIV exposure among incarcerated women 1st National Congress on HIV in Women, poster and abstract, Washington DC February, 1995
289. Sexual Abuse and HIV Risk Taking among Incarcerated Women HIV infection in Women, 1st National Meeting in Washington DC February, 1995
290. T cell response to Tuberculosis in HIV seropositive subjects; longitudinal and cross-sectional analysis poster and abstract, Keystone Symposium on the Molecular Mechanisms of Tuberculosis February, 1995
291. HIV and gynecological comorbidity among women incarcerated in Massachusetts, poster and abstract 1st National Congress on HIV in Women, Washington DC February, 1995
292. Discharge planning needs of incarcerated women living with HIV 1st National Congress on HIV in Women, Washington DC February, 1995
293. Peptide epitopes for five HIV-1 proteins predicted by a novel T cell epitope prediction algorithm poster and abstract, NCDVG conference, Washington DC October, 1994
294. Mycobacterium tuberculosis peptide epitopes predicted by two novel epitope identification algorithms poster and abstract, Molecular Approaches to the Control of Infectious Diseases, Cold Spring Harbor Laboratory October, 1994
295. Two novel algorithms for the identification of T cell epitopes that are based on MHC binding motifs poster and abstract, Molecular Approaches to the Control of Infectious Diseases Cold Spring Harbor Laboratory October, 1994
296. Two novel algorithms for the identification of T cell epitopes that are based on MHC binding motifs poster and abstract, Molecular Approaches to the Control of Infectious Diseases, Cold Spring Harbor Laboratory October, 1994
297. Mycobacterium tuberculosis peptide epitopes predicted by two novel epitope identification algorithms presentation and abstract, Molecular Approaches to the Control of Infectious Diseases, Cold Spring Harbor Laboratory October, 1994
298. Sexual Abuse and HIV Risk Taking among Incarcerated Women Women’s Health Conference September, 1994
299. Two Novel Computer Driven T Cell Epitope Prediction Algorithms for Vaccine Development Brown University Immunology Seminar, Brown University, Providence, RI September, 1994
300. A comparison of Cell-mediated responses to Mycobacterium tuberculosis (Mtb) antigens in Mtb-immune subjects and HIV-seronegative and HIV-seropositive Mtb-susceptible subjects poster and abstract, New Approaches to Vaccines including AIDS, Cold Spring Harbor Laboratory September, 1994
301. Sexual Abuse and HIV Risk Taking among Incarcerated Women Women’s Health Conference, Women & Infants Hospital September, 1994
302. Risks for HIV Infection, and Gynecological Comorbidity in Women Incarcerated in Massachusetts poster and abstract, Conference on Women's Health, Washington DC June, 1994
303. HIV in Incarcerated Women New England HIV in Prisons Conference May, 1994
304. HIV in Prisons conference HIV Update: Current State of the Art, Brown University AIDS program conference January, 1994
305. Battering and the Cycle of Violence Criminal Justice Institute conference December, 1993
306. Identification of antigenic regions of Mycobacterium tuberculosis proteins using Natural Peptide and Amphi algorithms poster and abstract, Conference on MultiDrug Resistant TB, Bethesda September, 1993
307. Prophylactic therapy for Toxoplasma Infection in HIV-1 Seropositive Subjects: Decision Analysis poster and abstract, IX International conference on AIDS, Berlin June, 1993
308. A Prospective Study of the Incidence of Reactivation of Latent Toxoplasma Infection in HIV-1-Seropositive Subjects in Massachusetts poster and abstract, IX International Conference on AIDS, Berlin June, 1993
309. Immunopathogenesis of an Epidemic: TB and HIV infection Grand Rounds, Lemuel Shattuck Hospital, Boston MA January, 1993
310. Tuberculosis: Multi Drug Resistant Tuberculosis and Drug Therapy Rounds, St. John's Hospital, Lowell MA December, 1992
311. Multi Drug Resistant Tuberculosis, Massachusetts Association of Physician's Assistants Annual Meeting, Falmouth, MA October, 1992
312. T Cell Responses to Mycobacterium tuberculosis in the HIV-infected Host Modern Approaches to New Vaccines, Cold Spring Harbor Laboratory September, 1992
313. Condoms and HIV Transmission Massachusetts Public School Board Panel July, 1992
314. Tuberculosis: Epidemiology and Treatment in the 1990's Pulmonary Rounds, St. John's Hospital, Lowell MA, December, 1991
315. Identification of a T-Helper cell epitope in HIV reverse transcriptase which is also recognized by CTL poster and abstract, New Approaches to Vaccines, Cold Spring Harbor Laboratory September, 1991
316. De-tolerization of anti-DEC-205 for HIV subunit vaccine delivery. HIV Immunobiology: From Infection to Immune Control (X4) March 22 - March 27, 2009 Keystone Resort, Keystone September, 1991



Site wide Speaking/Presenting-Abstract/Poster at Mtg

Presentation Event Month, Year
TRIAD TOOLKIT TRAINING Epitope Driven Vaccines – Recent History 1st Immunogenicity: Determinants and Correlates Conference May, 2011
GROUP DISCUSSIONS 1st Immunogenicity: Determinants and Correlates Conference May, 2011
Tregitope Overview | History | Status 1st Immunogenicity: Determinants and Correlates Conference May, 2011
Opening Remarks | Moderators 1st Immunogenicity: Determinants and Correlates Conference May, 2011
Lecture by 1st Immunogenicity: Determinants and Correlates Conference May, 2011
Closing Remarks 1st Immunogenicity: Determinants and Correlates Conference May, 2011
HLA as a biomarker – Putting the “personal” in vaccines and protein therapeutics 1st Immunogenicity: Determinants and Correlates Conference May, 2011
Break-out Discussion Groups: ASK THE EXPERTS Immunogenicity of Therapeutic Biologics May, 2010
Immunogenicity Problems: A Paradigm Shift? Antibody Engineering December, 2008
Decreasing the Cost of Developing Protein Products: Eradicating Immunogenicity by Screening, Re-engineering and Treg Induction Assessment of Immunogenicity in Clinical Trials April, 2008
Engineering Therapeutics (10:00-11:30) Antibodies Europe: Engineering the Next Generation of Antibodies Nov (07-08) November, 2007
Engineering Therapeutics: New Approaches to Immunogenicity: Screening, Reengineering and Modulation (10:30-11:00) Antibodies Europe: Engineering the Next Generation of Antibodies Nov (07-08) November, 2007

4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.